CpG methylation reduces genomic instability

Area of Science:

• Molecular Biology
• Cancer Genomics
• Epigenetics

Background:

• Tumor cells exhibit DNA hypomethylation, linked to genomic instability and mitotic recombination.
• Double minute chromosomes (DMs) are extrachromosomal DNA elements often found in cancer cells, amplifying oncogenes like dihydrofolate reductase (DHFR).
• Methotrexate resistance in tumor cells is associated with DHFR gene amplification on DMs.

Purpose of the Study:

• To investigate the role of DNA methylation patterns on double minute chromosomes in controlling genomic instability.
• To determine the relationship between CpG island methylation status and mitotic recombination frequency in DMs.
• To explore how epigenetic modifications on DMs influence tumor cell evolution and drug resistance.

Main Methods:

• Analysis of methylation patterns in double minute chromosomes from methotrexate-resistant mouse tumor cell lines (Mut F and Mut C) using methylation-sensitive rare-cutting restriction endonucleases.
• Assessment of DM size dynamics (dimerization, deletion) over time in continuous cell culture.
• Treatment with azacytidine to induce demethylation and subsequent analysis of DM structural changes.

Main Results:

• Unmethylated CpG islands on DMs in Mut F cells facilitated rapid dimerization, while partially methylated islands in Mut C cells were resistant to cleavage and structural changes.
• Demethylation of CpG islands in Mut C cells, induced by azacytidine or extended culture, sensitized DMs to cleavage and promoted deletions and dimerizations.
• The methylation status of CpG islands on DMs directly correlates with their susceptibility to mitotic recombination and subsequent structural alterations.

Conclusions:

• CpG island methylation status acts as a critical regulator of mitotic recombination frequency within and between large DNA molecules like DMs.
• Epigenetic control of recombination on DMs plays a significant role in driving genomic instability and adaptation in tumor cells.
• Targeting DNA methylation could offer novel therapeutic strategies to control tumor evolution and overcome drug resistance.